F Anthony Romero

7PUBLICATIONS
43CO-AUTHORS
Molecular targetsBiologically active moleculesAutonomic nervous systemCancer therapy (excl. chemotherapy and radiation therapy)Biomolecular modelling and design
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Nov 06, 2025
Enozertinib Is a Selective, Brain-Penetrant EGFR Inhibitor for Treating Non-Small Cell Lung Cancers with EGFR Exon 20 and Atypical Mutations.

Melissa R Junttila, Claire E Repellin, Sumeet Salaniwal

|Aug 05, 2022
GNE-064: A Potent, Selective, and Orally Bioavailable Chemical Probe for the Bromodomains of SMARCA2 and SMARCA4 and the Fifth Bromodomain of PBRM1.

Alexander M Taylor, Chris Bailey, Lisa D Belmont

|Jan 14, 2020
The Race to Bash NASH: Emerging Targets and Drug Development in a Complex Liver Disease.

F Anthony Romero, Christopher T Jones, Yingzi Xu

|Jun 12, 2019
CBP/p300 Drives the Differentiation of Regulatory T Cells through Transcriptional and Non-Transcriptional Mechanisms.

Joseph Castillo, Esther Wu, Christopher Lowe

|Nov 21, 2017
A Unique Approach to Design Potent and Selective Cyclic Adenosine Monophosphate Response Element Binding Protein, Binding Protein (CBP) Inhibitors.

Sarah M Bronner, Jeremy Murray, F Anthony Romero

|Oct 17, 2017
Hit-to-Lead Optimization and Discovery of 5-((5-([1,1'-Biphenyl]-4-yl)-6-chloro-1H-benzo[d]imidazol-2-yl)oxy)-2-methylbenzoic Acid (MK-3903): A Novel Class of Benzimidazole-Based Activators of AMP-Activated Protein Kinase.

Ping Lan, F Anthony Romero, Dariusz Wodka

Pageof 2

Frequent Collaborators

2 joint publications

Edna F Choo

2 joint publications

Terry D Crawford

2 joint publications

Patrick Cyr

1 joint publications

Stefan G Koenig